{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:13:43Z","timestamp":1790972023588,"version":"4.1.0"},"reference-count":29,"publisher":"e-Century Publishing Corporation","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/lhsf1117","type":"journal-article","created":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T03:13:17Z","timestamp":1727579597000},"page":"4688-4695","source":"Crossref","is-referenced-by-count":5,"title":["Expression and diagnostic value of abnormal prothrombin and osteopontin in hepatocellular carcinoma with cirrhosis"],"prefix":"10.62347","volume":"16","author":[{"given":"Guanjun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R and Saborowski A. Hepatocellular carcinoma. Lancet 2022; 400: 1345-1362.","journal-title":"Lancet"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cld.2022.08.004","article-title":"Hepatocellular carcinoma: new developments","volume":"27","author":"Ganesan","year":"2023","unstructured":"Ganesan P and Kulik LM. Hepatocellular carcinoma: new developments. Clin Liver Dis 2023; 27: 85-102.","journal-title":"Clin Liver Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"12239","DOI":"10.2147\/CMAR.S280631","article-title":"Cytotoxic chemotherapy as an alternative for systemic treatment of advanced hepatocellular carcinoma in developing countries","volume":"12","author":"Abouelezz","year":"2020","unstructured":"Abouelezz K, Khanapara D, Batiha GE, Ahmed EA and Hetta HF. Cytotoxic chemotherapy as an alternative for systemic treatment of advanced hepatocellular carcinoma in developing countries. Cancer Manag Res 2020; 12: 12239-12248.","journal-title":"Cancer Manag Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/cancers12040791","article-title":"Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update","volume":"12","author":"SA","year":"2020","unstructured":"Kishore SA, Bajwa R and Madoff DC. Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update. Cancers (Basel) 2020; 12: 791.","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","unstructured":"Toh MR, Wong EYT, Wong SH, Ng AWT, Loo LH, Chow PK and Ngeow J. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology 2023; 164: 766-782.","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/liv.14409","article-title":"The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida","volume":"40","author":"Pinheiro","year":"2020","unstructured":"Pinheiro PS, Medina HN, Callahan KE, Jones PD, Brown CP, Altekruse SF, McGlynn KA and Kobetz EN. The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida. Liver Int 2020; 40: 1201-1210.","journal-title":"Liver Int"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12885-021-08138-3","article-title":"PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma","volume":"21","author":"Feng","year":"2021","unstructured":"Feng H, Li B, Li Z, Wei Q and Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 2021; 21: 401.","journal-title":"BMC Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"8392","DOI":"10.1038\/s41467-023-44255-2","article-title":"Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma","volume":"14","author":"Xing","year":"2023","unstructured":"Xing X, Cai L, Ouyang J, Wang F, Li Z, Liu M, Wang Y, Zhou Y, Hu E, Huang C, Wu L, Liu J and Liu X. Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma. Nat Commun 2023; 14: 8392.","journal-title":"Nat Commun"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.cld.2020.07.001","article-title":"Role of biomarkers and biopsy in hepatocellular carcinoma","volume":"24","author":"Chen","year":"2020","unstructured":"Chen VL and Sharma P. Role of biomarkers and biopsy in hepatocellular carcinoma. Clin Liver Dis 2020; 24: 577-590.","journal-title":"Clin Liver Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3350\/cmh.2022.0421","article-title":"Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Taiwan perspective","volume":"29","author":"TH","year":"2023","unstructured":"Su TH, Wu CH, Liu TH, Ho CM and Liu CJ. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Taiwan perspective. Clin Mol Hepatol 2023; 29: 230-241.","journal-title":"Clin Mol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5582\/bst.2022.01061","article-title":"The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update","volume":"16","author":"Wen","year":"2022","unstructured":"Wen N, Cai Y, Li F, Ye H, Tang W, Song P and Cheng N. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update. Biosci Trends 2022; 16: 20-30.","journal-title":"Biosci Trends"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.semcancer.2021.07.017","article-title":"Epigenetics in hepatocellular carcinoma","volume":"86","author":"Nagaraju","year":"2022","unstructured":"Nagaraju GP, Dariya B, Kasa P, Peela S and El-Rayes BF. Epigenetics in hepatocellular carcinoma. Semin Cancer Biol 2022; 86: 622-632.","journal-title":"Semin Cancer Biol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","article-title":"Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification","volume":"149","author":"Chidambaranathan-Reghupaty S","year":"2021","unstructured":"Chidambaranathan-Reghupaty S, Fisher PB and Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res 2021; 149: 1-61.","journal-title":"Adv Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/JCMA.0000000000000915","article-title":"Minimally invasive surgery for hepatocellular carcinoma","volume":"86","author":"YT","year":"2023","unstructured":"Li YT, Yang ST and Wang PH. Minimally invasive surgery for hepatocellular carcinoma. J Chin Med Assoc 2023; 86: 457-458.","journal-title":"J Chin Med Assoc"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma","volume":"53","author":"Ramai","year":"2021","unstructured":"Ramai D, Singh J, Lester J, Khan SR, Chandan S, Tartaglia N, Ambrosi A, Serviddio G and Facciorusso A. Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma. Aliment Pharmacol Ther 2021; 53: 977-984.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jhep.2023.08.020","article-title":"AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation","volume":"79","author":"Norman","year":"2023","unstructured":"Norman JS, Li PJ, Kotwani P, Shui AM, Yao F and Mehta N. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol 2023; 79: 1469-1477.","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000537897","article-title":"Urgent global need for PIVKA-II and AFP-L3 measurements for surveillance and management of hepatocellular carcinoma","volume":"13","author":"Kudo","year":"2024","unstructured":"Kudo M. Urgent global need for PIVKA-II and AFP-L3 measurements for surveillance and management of hepatocellular carcinoma. Liver Cancer 2024; 13: 113-118.","journal-title":"Liver Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/pros.24055","article-title":"A hemi-spleen injection model of liver metastasis for prostate cancer","volume":"80","author":"Simons","year":"2020","unstructured":"Simons BW, Dalrymple S, Rosen M, Zheng L and Brennen WN. A hemi-spleen injection model of liver metastasis for prostate cancer. Prostate 2020; 80: 1263-1269.","journal-title":"Prostate"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41575-022-00620-y","article-title":"Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma","volume":"19","author":"Johnson","year":"2022","unstructured":"Johnson P, Zhou Q, Dao DY and Lo YMD. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022; 19: 670-681.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref19","unstructured":"Yu Z, Li G, Yuan N and Ding W. Comparison of ultrasound guided versus CT guided radiofrequency ablation on liver function, serum PIVKA-II, AFP levels and recurrence in patients with primary hepatocellular carcinoma. Am J Transl Res 2021; 13: 6881-6888."},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Hu X, Chen R, Wei Q and Xu X. The landscape of alpha fetoprotein in hepatocellular carcinoma: where are we? Int J Biol Sci 2022; 18: 536-551.","DOI":"10.7150\/ijbs.64537"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/medicina58081015","article-title":"Utility of PIVKA-II and AFP in differentiating hepatocellular carcinoma from non-malignant high-risk patients","volume":"58","author":"Hadi","year":"2022","unstructured":"Hadi H, Wan Shuaib WMA, Raja Ali RA and Othman H. Utility of PIVKA-II and AFP in differentiating hepatocellular carcinoma from non-malignant high-risk patients. Medicina (Kaunas) 2022; 58: 1015.","journal-title":"Medicina (Kaunas)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.33393\/jcb.2023.2453","article-title":"PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients","volume":"12","author":"Suttichaimongkol","year":"2023","unstructured":"Suttichaimongkol T, Mitpracha M, Tangvoraphonkchai K, Sadee P, Sawanyawisuth K and Sukeepaisarnjaroen W. PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients. J Circ Biomark 2023; 12: 12-16.","journal-title":"J Circ Biomark"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"17866","DOI":"10.1002\/cam4.6422","article-title":"Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery","volume":"12","author":"Cai","year":"2023","unstructured":"Cai Y, Xie K, Adeeb Alhmoud MN, Lan T, Wan H, Hu D, Lan L, Liu C and Wu H. Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery. Cancer Med 2023; 12: 17866-17877.","journal-title":"Cancer Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1010428317705763","DOI":"10.1177\/1010428317705763","article-title":"Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients","volume":"39","author":"Huang","year":"2017","unstructured":"Huang S, Jiang F, Wang Y, Yu Y, Ren S, Wang X, Yin P and Lou J. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients. Tumour Biol 2017; 39: 1010428317705763.","journal-title":"Tumour Biol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/labmed\/lmac027","article-title":"Usefulness of AFP, PIVKA-II, and their combination in diagnosing hepatocellular carcinoma based on upconversion luminescence immunochromatography","volume":"53","author":"Zhang","year":"2022","unstructured":"Zhang SG and Huang Y. Usefulness of AFP, PIVKA-II, and their combination in diagnosing hepatocellular carcinoma based on upconversion luminescence immunochromatography. Lab Med 2022; 53: 488-494.","journal-title":"Lab Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.17691\/stm2021.13.1.03","article-title":"Search for effective serum tumor markers for early diagnosis of hepatocellular carcinoma associated with hepatitis C","volume":"13","author":"Malov","year":"2021","unstructured":"Malov SI, Malov IV, Kuvshinov AG, Marche PN, Decaens T, Macek-Jilkova Z and Yushchuk ND. Search for effective serum tumor markers for early diagnosis of hepatocellular carcinoma associated with hepatitis C. Sovrem Tekhnologii Med 2021; 13: 27-33.","journal-title":"Sovrem Tekhnologii Med"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Jang ES, Jeong SH, Kim JW, Choi YS, Leissner P and Brechot C. Diagnostic performance of alpha-fetoprotein, protein induced by vitamin k absence, osteopontin, dickkopf-1 and its combinations for hepatocellular carcinoma. PLoS One 2016; 11: e0151069.","DOI":"10.1371\/journal.pone.0151069"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"8925","DOI":"10.2147\/OTT.S186230","article-title":"Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis","volume":"11","author":"Sun","year":"2018","unstructured":"Sun T, Tang Y, Sun D, Bu Q and Li P. Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2018; 11: 8925-8935.","journal-title":"Onco Targets Ther"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/9\/ajtr0157972.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:51Z","timestamp":1766022951000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/9\/ajtr0157972.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/lhsf1117","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}